Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 2,817 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sample Collection Blood Clear all
Recruiting No phase listed Observational

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

NCT02688517
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
1 Year and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
11
States / cities
Brick, New Jersey • Holmdel, New Jersey • Jersey City, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Completed No phase listed Observational

Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

NCT05945290
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma, Locally Advanced Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Nov 9, 2026, 5:34 AM EST
Not yet recruiting Phase 2 Interventional

Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial

NCT07910435
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab, Bone Marrow Biopsy, Core Biopsy, FDG-Positron Emission Tomography and Computed Tomography Scan, Neurologic Examination, Patient Observation, Biospecimen Collection, Bone Marrow Aspiration
Drug · Biological · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2038
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Addressing Colorectal Cancer in South Florida Firefighters

NCT05976282
View directory record Official record
Conditions
Colorectal Cancer, CRC
Interventions
Fecal Immunochemical Test, Septin9 Test
Other
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 65 Years
Enrollment
646 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Nov 9, 2026, 5:34 AM EST
Recruiting No phase listed Observational

Exosomes in Rectal Cancer

NCT03874559
View directory record Official record
Conditions
Rectal Cancer
Interventions
Blood Draw
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Recruiting No phase listed Observational

Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass

NCT07132788
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
blood draw, Short Performance Physical Battery, Grip strength test, Six minute walk test, Chest CT scan, Dual-Energy X-ray Absorptiometry Scan, Activity monitoring, 24 hour diet recall, Echocardiogram, Quality of Life Questionnaire (emPHasis 10), International Physical Activity Questionnaire Short Form (IPAQ-SF)
Diagnostic Test · Radiation · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Spectroscopy (MRS) in Midlife Depression

NCT02567110
View directory record Official record
Conditions
Depression, Depression Bipolar
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
35 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Nov 9, 2026, 5:34 AM EST
Active, not recruiting Phase 1 Interventional

Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH.

NCT07751120
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927
View directory record Official record
Conditions
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Neurotoxicity and Cardiotoxicity in Total Joint Arthroplasty

NCT04166539
View directory record Official record
Conditions
Metallosis, Pain, Total Hip Replacement, Total Knee Replacement
Interventions
Questionnaires, Interviews, Blood draw, Magnetic Resonance Imaging, Echocardiogram
Behavioral · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Nov 9, 2026, 5:34 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Johns Hopkins Breast Cancer Program Longitudinal Repository

NCT01937039
View directory record Official record
Conditions
Breast Cancer, Benign Breast Disease
Interventions
Sample collection
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Completed No phase listed Observational

Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines

NCT01191853
View directory record Official record
Conditions
Healthy Volunteers, Influenza
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

NCT04535401
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Elimusertib, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Duarte, California • Bethesda, Maryland • City of Saint Peters, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Completed No phase listed Observational

PK-PD Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients

NCT00281619
View directory record Official record
Conditions
Kidney Transplant
Interventions
CellCept (mycophenolate mofetil), Dietary Monitoring, Drug Diary, Blood Sampling
Drug · Behavioral · Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Nov 9, 2026, 5:34 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

NCT03854474
View directory record Official record
Conditions
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Tazemetostat
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Derby, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Active, not recruiting No phase listed Observational

Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics

NCT03348280
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension, Vitamin D Deficiency
Interventions
Blood draw
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Timeline
2017 – 2026
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Nov 9, 2026, 5:34 AM EST
Completed No phase listed Observational

JC-Virus (JCV) Antibody Program

NCT01070823
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri® (natalizumab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
1,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Cullman, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Nov 9, 2026, 5:34 AM EST
Terminated No phase listed Observational

Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy

NCT01934179
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
70 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Nov 9, 2026, 5:34 AM EST
Active, not recruiting Phase 3 Interventional

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
864
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Active, not recruiting Phase 2 Interventional

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

NCT05111574
View directory record Official record
Conditions
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
142
States / cities
Auburn, California • Berkeley, California • Fremont, California + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 9, 2026, 5:34 AM EST
Not listed No phase listed Observational

A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis

NCT04743323
View directory record Official record
Conditions
Pancreatitis, Acute, Alcohol Drinking, Health Behavior
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Nov 9, 2026, 5:34 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Ascertainment of Saliva or Blood Samples For Genetic Epidemiology Studies of Cancer and Aging

NCT00579618
View directory record Official record
Conditions
Non-cancer Affected Volunteers
Interventions
Saliva or Blood samples
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Nov 9, 2026, 5:34 AM EST
Terminated Phase 2 Interventional Results available

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

NCT01227018
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
STA-9090, Radiologic imaging, blood draw
Drug · Radiation · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Memphis, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Nov 9, 2026, 5:34 AM EST
Active, not recruiting No phase listed Observational

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

NCT05228275
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Survey Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 37 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
72
States / cities
Birmingham, Alabama • Kingman, Arizona • Oakland, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 9, 2026, 5:34 AM EST